CA2025668A1 - Use of omeprazole as an antimicrobial agent - Google Patents
Use of omeprazole as an antimicrobial agentInfo
- Publication number
- CA2025668A1 CA2025668A1 CA2025668A CA2025668A CA2025668A1 CA 2025668 A1 CA2025668 A1 CA 2025668A1 CA 2025668 A CA2025668 A CA 2025668A CA 2025668 A CA2025668 A CA 2025668A CA 2025668 A1 CA2025668 A1 CA 2025668A1
- Authority
- CA
- Canada
- Prior art keywords
- omeprazole
- antimicrobial agent
- methoxy
- plori
- campylobacter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004599 antimicrobial Substances 0.000 title 1
- 229960000381 omeprazole Drugs 0.000 title 1
- 241000589876 Campylobacter Species 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
Use of 5-methoxy-2-[[(4 methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1H-benzimidazole or a pharmaceutically acceptable salt thereof in the treatment of infectious diseases, especially such caused by Campylobacter plori.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1030311A JP2694361B2 (en) | 1989-02-09 | 1989-02-09 | Antibacterial agent |
JP30311/1989 | 1989-02-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2025668A1 true CA2025668A1 (en) | 1990-08-10 |
CA2025668C CA2025668C (en) | 1998-09-15 |
Family
ID=12300238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002025668A Expired - Lifetime CA2025668C (en) | 1989-02-09 | 1990-02-02 | Use of omeprazole as an antimicrobial agent |
Country Status (19)
Country | Link |
---|---|
US (1) | US5093342A (en) |
EP (1) | EP0414847B1 (en) |
JP (1) | JP2694361B2 (en) |
KR (1) | KR0140236B1 (en) |
AT (1) | ATE94063T1 (en) |
AU (1) | AU626641B2 (en) |
CA (1) | CA2025668C (en) |
CY (1) | CY1909A (en) |
DE (1) | DE69003207T2 (en) |
DK (1) | DK0414847T3 (en) |
ES (1) | ES2058892T3 (en) |
HK (1) | HK52196A (en) |
HU (1) | HU205253B (en) |
IE (1) | IE65814B1 (en) |
IL (1) | IL93263A0 (en) |
LV (1) | LV10577B (en) |
MY (1) | MY111737A (en) |
PH (1) | PH26787A (en) |
WO (1) | WO1990009175A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE114114T1 (en) * | 1989-02-10 | 1994-12-15 | Takeda Chemical Industries Ltd | USE OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS. |
GB9018603D0 (en) * | 1990-08-24 | 1990-10-10 | Smith Kline French Lab | Compositions |
ES2169022T3 (en) * | 1990-09-14 | 2002-07-01 | Byk Gulden Lomberg Chem Fab | USE OF DERIVATIVES OF (PIRIDIL-METIL-SULFINIL) -1-H-BENCIMIDAZOL FOR THE TREATMENT OF DISEASES CAUSED BY HELICOBACTER. |
IS3990A (en) * | 1992-04-24 | 1993-10-25 | Ab Astra | Method of mixing substances that inhibit gastric acid and bacterial degrading agent in an acidic environment |
US5504082A (en) * | 1992-06-01 | 1996-04-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridine compound and pharmaceutical compostions |
EP0673246A1 (en) * | 1992-12-10 | 1995-09-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | Use of alkylthiopyridines for controlling helicobacter bacteria |
US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
US6902738B2 (en) * | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
US5834002A (en) * | 1994-05-02 | 1998-11-10 | Josman Laboratories, Inc. | Chewing gum containing colloidal bismuth subcitrate |
US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
AU4596796A (en) * | 1995-02-07 | 1996-08-27 | Narayan Krishnarao Athanikar | Concomitant treatment with bismuth and antibacterials |
US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
SI9700186B (en) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Novel pharmaceutical preparation with controlled release of active healing substances |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SI1037634T1 (en) * | 1997-12-08 | 2006-02-28 | Altana Pharma Ag | Oral administration form comprising a proton pump inhibitor (e.g.pantoprazole) |
AU2031799A (en) | 1998-01-14 | 1999-08-02 | Uab Research Foundation, The | Methods of synthesizing and screening inhibitors of bacterial nad synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial nad synthetase enzyme |
US6861448B2 (en) * | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6780880B1 (en) * | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
SE0002476D0 (en) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
JP2005521662A (en) * | 2002-01-25 | 2005-07-21 | サンタラス インコーポレイティッド | Transmucosal delivery of proton pump inhibitors |
WO2004073654A2 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
CA2531566C (en) * | 2003-07-18 | 2013-05-07 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
EP1648416A4 (en) * | 2003-07-18 | 2012-03-28 | Santarus Inc | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
PT2003130E (en) | 2006-03-10 | 2012-01-10 | Arigen Pharmaceuticals Inc | Novel pyridine derivative having anti-helicobacter pylori activity |
KR20090071598A (en) | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | Treatment of liver disorders by administration of receptor-associated protein(rap)-conjugates |
CA2665226C (en) | 2006-10-05 | 2014-05-13 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
EP2486910A3 (en) | 2006-10-27 | 2012-08-22 | The Curators Of The University Of Missouri | Multi-chambered apparatus comprising a dispenser head |
AU2007335663B2 (en) | 2006-12-18 | 2011-12-15 | Link Genomics, Inc. | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
EP3395372B1 (en) | 2009-02-20 | 2022-04-06 | EnhanX Biopharm Inc. | Glutathione-based drug delivery system |
KR101353572B1 (en) | 2009-04-09 | 2014-01-22 | 링크 제노믹스 가부시키가이샤 | Pyridine thio derivative, and pharmaceutical composition which contains same and has anti-helicobacter pylori action |
IL255113B (en) | 2009-05-06 | 2022-09-01 | Laboratory Skin Care Inc | Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same |
US8722026B2 (en) | 2010-01-06 | 2014-05-13 | Elc Management, Llc | Skin lightening compositions |
US8992897B2 (en) | 2010-01-06 | 2015-03-31 | Elc Management Llc | Skin lightening compositions |
US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
KR101628474B1 (en) * | 2014-08-27 | 2016-06-08 | 경북대학교 산학협력단 | Cosmetic composition for skin whitening comprising of omeprazole |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
SE8301182D0 (en) * | 1983-03-04 | 1983-03-04 | Haessle Ab | NOVEL COMPOUNDS |
MY103790A (en) * | 1987-10-30 | 1993-09-30 | Ab Hassle | Novel compound for the treatment of several bone affecting diseases |
-
1989
- 1989-02-09 JP JP1030311A patent/JP2694361B2/en not_active Expired - Lifetime
-
1990
- 1990-02-02 WO PCT/SE1990/000070 patent/WO1990009175A1/en active IP Right Grant
- 1990-02-02 CY CY190990A patent/CY1909A/en unknown
- 1990-02-02 KR KR1019900702221A patent/KR0140236B1/en not_active IP Right Cessation
- 1990-02-02 DE DE90902854T patent/DE69003207T2/en not_active Expired - Fee Related
- 1990-02-02 DK DK90902854.0T patent/DK0414847T3/en active
- 1990-02-02 US US07/572,951 patent/US5093342A/en not_active Expired - Fee Related
- 1990-02-02 CA CA002025668A patent/CA2025668C/en not_active Expired - Lifetime
- 1990-02-02 EP EP90902854A patent/EP0414847B1/en not_active Expired - Lifetime
- 1990-02-02 HU HU901539A patent/HU205253B/en not_active IP Right Cessation
- 1990-02-02 IL IL93263A patent/IL93263A0/en not_active IP Right Cessation
- 1990-02-02 AU AU50381/90A patent/AU626641B2/en not_active Ceased
- 1990-02-02 ES ES90902854T patent/ES2058892T3/en not_active Expired - Lifetime
- 1990-02-02 AT AT90902854T patent/ATE94063T1/en not_active IP Right Cessation
- 1990-02-06 IE IE41890A patent/IE65814B1/en not_active IP Right Cessation
- 1990-02-09 MY MYPI90000213A patent/MY111737A/en unknown
- 1990-02-09 PH PH40033A patent/PH26787A/en unknown
-
1994
- 1994-08-30 LV LVP-94-169A patent/LV10577B/en unknown
-
1996
- 1996-03-21 HK HK52196A patent/HK52196A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE94063T1 (en) | 1993-09-15 |
CA2025668C (en) | 1998-09-15 |
ES2058892T3 (en) | 1994-11-01 |
DK0414847T3 (en) | 1993-12-13 |
KR910700048A (en) | 1991-03-13 |
US5093342A (en) | 1992-03-03 |
IL93263A0 (en) | 1990-11-29 |
HU901539D0 (en) | 1991-02-28 |
IE900418L (en) | 1990-08-09 |
MY111737A (en) | 2000-12-30 |
AU5038190A (en) | 1990-09-05 |
LV10577B (en) | 1995-10-20 |
IE65814B1 (en) | 1995-11-15 |
HUT54890A (en) | 1991-04-29 |
WO1990009175A1 (en) | 1990-08-23 |
CY1909A (en) | 1990-02-02 |
JPH02209809A (en) | 1990-08-21 |
HU205253B (en) | 1992-04-28 |
JP2694361B2 (en) | 1997-12-24 |
LV10577A (en) | 1995-04-20 |
HK52196A (en) | 1996-03-29 |
EP0414847B1 (en) | 1993-09-08 |
AU626641B2 (en) | 1992-08-06 |
KR0140236B1 (en) | 1998-06-01 |
DE69003207D1 (en) | 1993-10-14 |
EP0414847A1 (en) | 1991-03-06 |
PH26787A (en) | 1992-10-13 |
DE69003207T2 (en) | 1994-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2025668A1 (en) | Use of omeprazole as an antimicrobial agent | |
CA2284470A1 (en) | New crystalline form of omeprazole | |
CA2011532A1 (en) | Formulation | |
EP1020460A3 (en) | The sodium salt of the (-)-enantiomer of omeprazole | |
CA2005986A1 (en) | Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation | |
HK1123985A1 (en) | Amorphous (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2- pyridinyl]methyl]sulfinyl]-1h-benzimidazole as anti-ulcer agent | |
CA2274076A1 (en) | Crystalline form of s-omeprazole | |
EP0392959A3 (en) | Use of sertindole for the treatment of schizophrenia | |
AU6973991A (en) | Therapeutically active chloro substituted benzimidazoles, processes for their preparation as well as their use | |
EP1191025A4 (en) | Crystals of benzimidazole compounds | |
AP9100285A0 (en) | Substituted benzimidazoles,process for their preparation and their pharmaceutical use | |
HU901085D0 (en) | Process for producing substituted benzimidazole and pharmaceutical preparatives containing it | |
ZA989999B (en) | New process for the preparation of 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)1H-benzimidazole | |
CA2089748A1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl]benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
DE59001121D1 (en) | Antacidatabletten. | |
ES2060293T3 (en) | NEW ANTI-ULCER SUBSTANCE. | |
AR242498A1 (en) | Procedure for the preparation of a pharmaceutical compound, useful for treating vascular infections or illnesses. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |